Last reviewed · How we verify
Ligilactobacillus salivarius MP101 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Ligilactobacillus salivarius MP101 (Ligilactobacillus salivarius MP101) — Universidad Complutense de Madrid.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ligilactobacillus salivarius MP101 TARGET | Ligilactobacillus salivarius MP101 | Universidad Complutense de Madrid | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ligilactobacillus salivarius MP101 CI watch — RSS
- Ligilactobacillus salivarius MP101 CI watch — Atom
- Ligilactobacillus salivarius MP101 CI watch — JSON
- Ligilactobacillus salivarius MP101 alone — RSS
Cite this brief
Drug Landscape (2026). Ligilactobacillus salivarius MP101 — Competitive Intelligence Brief. https://druglandscape.com/ci/ligilactobacillus-salivarius-mp101. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab